BMS-817378

CAS No. 1174161-69-3

BMS-817378( BMS817378 )

Catalog No. M10591 CAS No. 1174161-69-3

BMS-817378 is a prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 69 In Stock
10MG 117 In Stock
25MG 188 In Stock
50MG 276 In Stock
100MG 421 In Stock
200MG 607 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BMS-817378
  • Note
    Research use only, not for human use.
  • Brief Description
    BMS-817378 is a prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833.
  • Description
    BMS-817378 is a prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833.Solid Tumors Phase 1 Clinical.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    BMS817378
  • Pathway
    Angiogenesis
  • Target
    c-Met/HGFR
  • Recptor
    c-Met/HGFR
  • Research Area
    Cancer
  • Indication
    Solid Tumors

Chemical Information

  • CAS Number
    1174161-69-3
  • Formula Weight
    578.85
  • Molecular Formula
    C24H18ClF2N4O7P
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C1=CC(=CC=C1C2=CN(C=C(C2=O)C(=O)NC3=CC(=C(C=C3)OC4=C(C(=NC=C4)N)Cl)F)COP(=O)(O)O)F
  • Chemical Name
    (Z)-N-(4-((3-chloro-2-imino-1,2-dihydropyridin-4-yl)oxy)-3-fluorophenyl)-5-(4-fluorophenyl)-4-oxo-1-((phosphonooxy)methyl)-1,4-dihydropyridine-3-carbimidic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • MK-2461

    MK-2461 is a potent multitargeted kinase inhibitor that preferentially inhibits c-Met with IC50 of 2.5 nM.

  • MET inhibitor Compou...

    A novel potent, selective orally bioavailable MET tyrosine kinase inhibitor with IC50 of <1 nM and 12 nM for unphosphorylated and phosphorylaed MET, respectively.

  • Salidroside

    Salidroside is a bioactive phenolic glycoside compound isolated from Rhodiola crenulata. It is a prolyl endopeptidase Inhibitor.